Eosinophilic Esophagitis: Towards Improved Management
Launched by OSLO UNIVERSITY HOSPITAL · May 27, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the care and management of eosinophilic esophagitis, a condition that affects the esophagus and can cause difficulty swallowing and other symptoms. The trial is being conducted in collaboration with pediatric units in Norway and aims to explore new and existing tests that can help doctors diagnose and monitor the condition without needing as many invasive procedures, like endoscopies. This means that children and teenagers could spend less time on strict diets and have a more comfortable experience managing their condition.
To participate in this trial, individuals must either have a confirmed diagnosis of eosinophilic esophagitis or have symptoms that suggest they might have it. The trial is open to all genders and is currently recruiting participants. It is important to note that those with serious chronic health issues that would make anesthesia unsafe, or who do not give consent, will not be eligible to take part. Participants can expect to engage in a study that aims to make living with eosinophilic esophagitis easier and more manageable.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • a diagnosis of eosinophilic esophagitis
- • suspected but not yet confirmed eosinophilic esophagitis
- Exclusion Criteria:
- • chronic severe conditions that preclude general anaestesia
- • lack of consent
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Oslo, , Norway
Patients applied
Trial Officials
Ketil Størdal, PhD
Principal Investigator
University of Oslo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported